SEOUL, South Korea, Oct. 17, 2023 /PRNewswire/ -- ImmunoForge today announced that it has dosed the first patient in its Phase 2 clinical trial to evaluate the efficacy, safety, and pharmacokinetic properties of Froniglutide in patients with dermatomyositis/polymyositis.
SEOUL, South Korea, May 18, 2023 /PRNewswire/ -- ImmunoForge has announced on the 18th that it has expanded its license rights with Duke University to enhance joint research and drug development opportunities in relation to the elastin-like polypeptide (ELP) platform technology. Through this agreement, ImmunoForge expects to accelerate the development of new drugs based on the ELP technology that was originally developed by Professor Ashutosh Chilkoti at Duke University. Dr. Jim Ballance, Chief Technology Officer (CTO) of ImmunoForge, has pioneered the clinical development of peptide drugs that are genetically fused to ELPs. The powerful research partnership between ImmunoForge and Duke University will revolutionize the delivery of peptide and protein drugs.
SEOUL, South Korea, Sept. 27, 2021 /PRNewswire/ -- Immunoforge (Co-CEOs Sung-min Ahn, Kiho Chang), a company specializing in developing new drugs for rare musculoskeletal diseases, has reported that their new drug candidate PF1801 has received Orphan Drug Designation (ODD) from the U.S. FDA for the treatment of Polymyositis.